In recent years, a novel class of CD64 directed immunotherapeutic agents have emerged for the treatment of macrophage-mediated chronic inflammatory diseases such as chronic cutaneous inflammation, rheumatoid arthritis, chronic diabetic wounds (CDW), etc. They have been accompanied by positive in vitro, in vivo and ex vivo results which make them highly promising candidates for clinical trials [48]. This evidence concerns the gene FCGR1A and rheumatoid arthritis.